RE: Products and development17 Nov 2025 09:30
SocialistB ... As we heard on the interview with vlad, he is keen now to sell the company at the right value. For me and most people that could be anywhere between $1bn for just CART at the lowest price and upto $10bn if CDX or CBR gets more validation and into the clinic or close. Estonia being a possible solid revenue opportunity in Q1 and beyond and who knows what else Vlad is working on in the background, I feel hemo has been suppressed and subdued for so long it is only a matter of time before it gets the attention it deserves.
Dec 1st we will hear about late Ash submissions and we know tech transfer and injections for P4 and P1 kids is close so this is a silly irrelevant price at just around £50m MCAP. Many are waiting on the sidelines and waiting for the traders and big boys to arrive but with such little stock in circulation and over 80,000 shorts open, we are getting ready for some real fireworks before end year.
Don't worry, the LTHs have money if vlad would need it sometime in 2026 but that is very unlikely as vlad courts many pharma under NDA and we just wait for the true value of hemo to materialise. Things could get very exciting very soon starting this week ...
GO HEMO GO !!!